Whoop’s quiet FDA win and the bigger story behind it
The Whoop FDA blood pressure saga is the story of a fitness band maker that pushed back against regulators over a wellness feature, kept its blood pressure estimation live, and ultimately secured permission to keep offering it after agreeing to change its wording and positioning in the app. That framing matters, because Whoop did not invent a new medical device; like many wearables, its band cannot measure blood pressure directly and instead estimates changes based on sensor data after users first calibrate with a traditional cuff. Last August, the FDA contacted Whoop with concerns about this analysis and the way it was labeled in the app. Whoop pushed back, negotiated, and never disabled the feature, while the agency weighed whether this blood pressure tool crossed the line from wellness insight into regulated medical diagnosis.
From medical device risk to wellness label: why wording saved Whoop
The FDA’s problem was not that Whoop estimated blood pressure, but that its language risked turning a fitness tracker into a regulated medical device, pulling it into full health tracker regulation. Like many other wearables, Whoop’s band relies on a cuff-based baseline and then infers changes from sensors rather than measuring pressure directly. According to Bloomberg, the agency has now formally allowed Whoop to keep its blood pressure tool, after it removed labels marking readings as “normal” or “elevated” and reframed the feature as a wellness insight instead of a diagnostic claim. The FDA also stated it will not take enforcement action against Whoop nearly a year after its initial warning about the blood pressure tracker. This is less a technological victory than a semantic one: in the current regulatory climate, how you describe a feature can matter as much as how it works.
Wearable subscription workaround: Noop, Goose, and the rebellion against locks
While Whoop negotiated with regulators, a different challenge emerged from independent wearable apps. Whoop sells a screenless fitness tracker that streams heart rate and motion data to a phone app, which then uploads to the cloud for analysis, typically behind a USD 239 (approx. RM1105) per year subscription. Many users have since upgraded from the 4.0 strap to the free 5.0 replacement, leaving older bands as e‑waste. Developers saw an opportunity: if a phone can speak the right Bluetooth Low Energy language, it can pair with a fresh Whoop device and read data without touching Whoop’s servers. That’s the idea behind wearable subscription workaround projects like Noop, Goose, and others, which let individuals use Whoop hardware with no subscription and no contact with the company at all. Some apps have already been taken down after requests from Whoop executives, underscoring how contested this space is.
Independent apps split hardware and software—and threaten the old model
Independent developers ask a simple question: if you bought or received the hardware, why shouldn’t you decide which software reads its sensors? From early experiments like Whoomp, which could show heart rate and trigger vibrations from a dormant Whoop 4.0 strap, to newer tools that decode more of the Bluetooth protocol, the goal is the same—an independent wearable app that can fully replace the official client. A few weeks ago, a hobbyist proved this was practical by posting code that connected to old Whoop 4.0 straps, inspiring more apps on Reddit and GitHub before some were removed. If a free app can read a band’s data directly, users can keep using their hardware without the Whoop app or subscription service, turning obsolete straps into useful tools again. These projects separate the physical tracker from the proprietary cloud ecosystem, and in the process force hard questions about whether subscriptions are a service fee or a lock on hardware people already wear.
What this means for the next wave of health trackers
Taken together, Whoop’s blood pressure outcome and the rise of workaround apps show that the next battle over wearables is about control as much as innovation. On one side, regulators signal that they are less interested in banning health tracker features outright and more focused on how companies present them, especially when wellness language shades into medical claims. On the other, independent projects show there is demand for open access to sensor data, both to protect privacy and to avoid expensive subscriptions. Users gain short‑term wins—Whoop members keep their blood pressure insights, and owners of old bands can resurrect them—but the industry now faces a choice. Either embrace models where hardware and data stay useful beyond a paywall, or double down on locked ecosystems and invite more workarounds. In wearables, the real competition may end up being between platforms that trust users and those that try to fence them in.
